A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(6 sites)

Democratic Republic of the Congo

University of Kinshasa UNIKIN, Kinshasa

Institute National de Recherche Biomedicale, Kinshasa

South Africa

TASK Applied Science, Cape Town

TREAD Research Pty Ltd, Cape Town

Desmond Tutu Health Foundation Masiphumelele Clinic, Cape Town

Perinatal HIV Research Unit, Johannesburg